Fractyl Health (GUTS) Stock Price, News & Analysis

Company Overview

Fractyl Health, Inc. is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine. This outpatient procedure is designed to interrupt disease-driving signals between the gut and the liver, pancreas and brain, with the aim of improving glycemic control and reducing liver fat. Fractyl has conducted multiple clinical trials across North America, Europe and Asia, and holds CE mark approval in the European Union for Revita DMR.

Fractyl Health is also developing next-generation therapies and combination approaches to expand the reach of its duodenal resurfacing technology. The company has initiated pivotal studies to support U.S. regulatory filings and is preparing for broader commercial roll-out following anticipated approvals. Fractyl’s management team includes industry veterans in interventional gastroenterology, clinical development and medical device commercialization, positioning the company to address the growing global burden of metabolic disease.

Key Stats

• Today's Range: $0.92 to $0.99
• 50-Day Range: $0.90 to $1.97
• 52-Week Range: $0.83 to $3.48
• Volume: 366,484 shs
• Average Volume: 503,178 shs
• Market Capitalization: $48.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.53
• Consensus Rating: Buy

Fractyl Health Stock Analysis - MarketRank™

Fractyl Health scored higher than 35% of companies evaluated by MarketBeat, and ranked 775th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Fractyl Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Fractyl Health has a consensus price target of $6.53, representing about 579.8% upside from its current price of $0.96.

Amount of Analyst Coverage

Fractyl Health has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fractyl Health are expected to decrease in the coming year, from ($1.61) to ($1.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fractyl Health is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fractyl Health is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fractyl Health has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.76% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fractyl Health has recently increased by 20.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fractyl Health does not currently pay a dividend.

Dividend Growth

Fractyl Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.76% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fractyl Health has recently increased by 20.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Fractyl Health this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for GUTS on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fractyl Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.10% of the stock of Fractyl Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

GUTS Stock Analysis - Frequently Asked Questions

How have GUTS shares performed this year?

Fractyl Health's stock was trading at $2.06 at the beginning of 2025. Since then, GUTS stock has decreased by 53.3% and is now trading at $0.9610.

How were Fractyl Health's earnings last quarter?

Fractyl Health, Inc. (NASDAQ:GUTS) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.16. Fractyl Health had a negative net margin of 73,864.52% and a negative trailing twelve-month return on equity of 584.35%.
Read the conference call transcript.

When did Fractyl Health IPO?

Fractyl Health (GUTS) raised $110 million in an IPO on Friday, February 2nd 2024. The company issued 7,333,333 shares at $15.00 per share.

Who are Fractyl Health's major shareholders?

Top institutional investors of Fractyl Health include General Catalyst Group Management LLC (9.97%), Y Intercept Hong Kong Ltd (0.23%), Geode Capital Management LLC (0.23%) and Qube Research & Technologies Ltd (0.16%). Insiders that own company stock include Ajay Royan, Harith Rajagopalan, Jay David Caplan and William Bradley.
View institutional ownership trends.

How do I buy shares of Fractyl Health?

Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fractyl Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fractyl Health investors own include SoFi Technologies (SOFI), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:GUTS
• Previous Symbol: NASDAQ:GUTS
• CIK: 1572616
• Web: fractyl.com
• Phone: 781-902-8800
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Fractyl Health: $6.53
• High Price Target: $10.00
• Low Price Target: $3.60
• Potential Upside/Downside: +599.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.69 million
• Net Margins: -73,864.52%
• Pretax Margin: -586,864.69%
• Return on Equity: -584.35%
• Return on Assets: -102.88%

Debt

• Debt-to-Equity Ratio: 4.61
• Current Ratio: 1.22
• Quick Ratio: 1.22

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 521.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 50,290,000
• Free Float: 37,164,000
• Market Cap: $46.97 million
• Optionable: N/A
• Beta: 1.58